Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Nitrated food proteins induce a regulatory immune response associated with allergy prevention after oral exposure in a Balb/c mouse food allergy model.

Samadi N, Klems M, Heiden D, Bauer R, Kitzmüller C, Weidmann E, Ret D, Ondracek AS, Duschl A, Horejs-Hoeck J, Untersmayr E.

Allergy. 2019 Aug 24. doi: 10.1111/all.14030. [Epub ahead of print]

PMID:
31444907
2.

Mouse Chow Composition Influences Immune Responses and Food Allergy Development in a Mouse Model.

Weidmann E, Samadi N, Klems M, Heiden D, Seppova K, Ret D, Untersmayr E.

Nutrients. 2018 Nov 16;10(11). pii: E1775. doi: 10.3390/nu10111775.

3.

Radiographic Measurement of Hindlimb Digit Length in Standing Heifers.

Muggli E, Weidmann E, Kircher P, Nuss K.

Anat Histol Embryol. 2016 Dec;45(6):463-468. doi: 10.1111/ahe.12222. Epub 2015 Dec 28.

PMID:
26706956
4.

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas.

Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Erratum in: Lancet Oncol. 2016 Jan;17(1):e6.

PMID:
26655425
5.

Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL.

Leuk Lymphoma. 2016;57(4):766-82. doi: 10.3109/10428194.2015.1099647. Epub 2015 Nov 23. Review.

6.

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.

Kirschey S, Flohr T, Wolf HH, Frickhofen N, Gramatzki M, Link H, Basara N, Peter N, Meyer RG, Schmitz N, Weidmann E, Banat A, Schulz A, Kolbe K, Derigs G, Theobald M, Hess G.

Br J Haematol. 2015 Mar;168(6):824-34. doi: 10.1111/bjh.13234. Epub 2014 Dec 28.

PMID:
25546611
7.

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H.

Eur J Cancer. 2015 Jan;51(1):27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5.

PMID:
25459392
8.

Arthrodesis of the proximal interphalangeal joints of a hindlimb in a heifer.

Muggli E, Weidmann E, Bruderer A, Nuss K.

Vet Comp Orthop Traumatol. 2015;28(1):67-72. doi: 10.3415/VCOT-14-04-0059. Epub 2014 Nov 14.

PMID:
25394407
9.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d'Amore F, Tilly H, Zinzani PL.

Cancer Treat Rev. 2014 Oct;40(9):1080-8. doi: 10.1016/j.ctrv.2014.08.001. Epub 2014 Aug 24. Review.

10.

[Claw size of Scottish Highland Cows after pasture and housing periods].

Nuss K, Kolp E, Braun U, Weidmann E, Hässig M.

Schweiz Arch Tierheilkd. 2014 Sep;156(9):433-40. doi: 10.1024/0036-7281/a000625. German.

11.

Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.

Karbach J, Gnjatic S, Biskamp M, Atmaca A, Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A, Jäger E.

Cancer Immunol Res. 2014 May;2(5):404-9. doi: 10.1158/2326-6066.CIR-13-0200. Epub 2014 Feb 5.

12.

[Hock lesions in dairy cows--an overview].

Nuss K, Weidmann E.

Tierarztl Prax Ausg G Grosstiere Nutztiere. 2013;41(4):234-44; quiz 245. German.

PMID:
23959619
13.

ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.

Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Apr 20;31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.

PMID:
23509310
14.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL).

Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20. Erratum in: Lancet. 2013 Apr 6;381(9873):1184.

PMID:
23433739
15.

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E.

Ann Oncol. 2011 Aug;22(8):1839-44. doi: 10.1093/annonc/mdq671. Epub 2011 Jan 21.

PMID:
21257672
16.

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N.

Bone Marrow Transplant. 2011 Aug;46(8):1045-52. doi: 10.1038/bmt.2010.249. Epub 2010 Oct 25.

PMID:
20972470
17.

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.

Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS.

Leuk Lymphoma. 2010 Mar;51(3):447-55. doi: 10.3109/10428190903580402.

PMID:
20141439
18.

Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.

Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E.

Int J Cancer. 2010 Feb 15;126(4):909-18. doi: 10.1002/ijc.24850.

19.

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.

Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M.

Leuk Lymphoma. 2009 May;50(5):716-22. doi: 10.1080/10428190902856790.

PMID:
19347767
20.

Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.

Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M.

Int J Hematol. 2008 Nov;88(4):434-440. doi: 10.1007/s12185-008-0176-2. Epub 2008 Oct 7.

PMID:
18839273
21.

LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.

Bender A, Karbach J, Neumann A, Jäger D, Al-Batran SE, Atmaca A, Weidmann E, Biskamp M, Gnjatic S, Pan L, Hoffman E, Old LJ, Knuth A, Jäger E.

Cancer Immun. 2007 Oct 19;7:16.

22.

Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.

Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H.

Leuk Lymphoma. 2007 Feb;48(2):349-56.

PMID:
17325896
23.

Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.

Al-Batran SE, Kerber A, Atmaca A, Dechow C, Reitsamer E, Schmidt S, Kolassa Y, Neumann A, Weidmann E, Hartmann JT, Jäger E.

Onkologie. 2007 Feb;30(1-2):29-34. Epub 2007 Jan 26.

PMID:
17264523
24.

Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.

Friedmann I, Atmaca A, Chow KU, Jäger E, Weidmann E.

J Chemother. 2006 Aug;18(4):415-20.

PMID:
17024798
25.

Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.

Willenbrock K, Küppers R, Renné C, Brune V, Eckerle S, Weidmann E, Bräuninger A, Hansmann ML.

Haematologica. 2006 May;91(5):596-604.

26.

In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling.

Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, Mitrou PS, Hoelzer D, Weidmann E, Hofmann WK.

Pharmacol Res. 2006 Jan;53(1):49-61. Epub 2005 Oct 5.

PMID:
16213748
27.

Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.

Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E.

Cancer Res. 2005 May 1;65(9):3937-41.

28.

Upon drug-induced apoptosis expression of prostate-apoptosis-response-gene-4 promotes cleavage of caspase-8, bid and mitochondrial release of cytochrome c.

Boehrer S, Kukoc-Zivojnov N, Nowak D, Bergmann M, Baum C, Puccetti E, Weidmann E, Hoelzer D, Mitrou PS, Chow KU.

Hematology. 2004 Oct-Dec;9(5-6):425-31.

PMID:
15763985
29.

Expression of Daxx sensitizes Jurkat T-cells to the apoptosis-inducing effect of chemotherapeutic agents.

Boehrer S, Nowak D, Kukoc-Zivojnov N, Hochmuth S, Kim SZ, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Pharmacol Res. 2005 Apr;51(4):367-74.

PMID:
15683751
30.

Daxx overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor- and drug-induced apoptosis in distinct ways.

Boehrer S, Nowak D, Hochmuth S, Kim SZ, Trepohl B, Afkir A, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Cell Signal. 2005 May;17(5):581-95.

PMID:
15683733
31.

In malignant myeloid cells expression of Daxx downregulates expression of p53 and of the inhibitors of apoptosis proteins.

Boehrer S, Nowak D, Schaaf S, Bergmann M, Brieger A, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Hematol J. 2004;5(6):513-8.

PMID:
15570294
32.

Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.

Kim SZ, Chow KU, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer SA, Harder L, Hoelzer D, Mitrou PS, Weidmann E.

Leuk Lymphoma. 2004 Oct;45(10):2037-45.

PMID:
15370248
33.

In the erythroleukemic cell line HEL Prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate Bcl-2 and to promote apoptosis.

Boehrer S, Brieger A, Schaaf S, Kukoc-Zivojnov N, Nowak D, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Leuk Lymphoma. 2004 Jul;45(7):1445-51.

PMID:
15359646
34.

Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus.

Nowak D, Boehrer S, Brieger A, Kim SZ, Schaaf S, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Leuk Lymphoma. 2004 Jul;45(7):1429-36.

PMID:
15359644
35.

Prostate apoptosis response gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis.

Bergmann M, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S.

Ann Hematol. 2004 Oct;83(10):646-53. Epub 2004 Aug 14.

PMID:
15316756
36.

Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.

Kukoc-Zivojnov N, Puccetti E, Chow KU, Bergmann M, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S.

Exp Hematol. 2004 Jul;32(7):649-56.

PMID:
15246161
37.

In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.

Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Biochem Pharmacol. 2004 Jul 1;68(1):85-93.

PMID:
15183120
38.

Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting.

Weidmann E, Gramatzki M, Wilhelm M, Mitrou PS.

Ann Oncol. 2004 Mar;15(3):369-74. No abstract available.

PMID:
14998837
40.

A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study.

Schilling D, Demel A, Adamek HE, Nüsse T, Weidmann E, Riemann JF.

Dig Liver Dis. 2003 Apr;35(4):217-21.

PMID:
12801031
42.
43.

CD4+ CD56+ neoplasia: clinical and biological features with emphasis on cytotoxic drug-induced apoptosis and expression of sialyl Lewis X.

Kim SZ, Zollner TM, Schui DK, Chow KU, Sterry W, Kriener S, Hoelzer D, Mitrou PS, Weidmann E.

Leuk Lymphoma. 2003 Feb;44(2):281-9. Review.

PMID:
12688346
44.

Expression and function of prostate-apoptosis-response-gene-4 in lymphatic cells.

Boehrer S, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E.

Leuk Lymphoma. 2002 Sep;43(9):1737-41.

PMID:
12685825
45.
46.

Cytotoxic activity of T- and NK-cell lymphoma cells is not dependent on a mature cytotoxic phenotype.

Boehrer S, Schui DK, Chow KU, Hoelzer D, Mitrou PS, Weidmann E.

Leuk Lymphoma. 2002 Dec;43(12):2363-8.

PMID:
12613525
47.

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.

Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS.

Ann Oncol. 2002 Aug;13(8):1285-9.

PMID:
12181253
48.

In vitro studies with bendamustine: enhanced activity in combination with rituximab.

Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E.

Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4.

PMID:
12170426
49.

Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.

Chow KU, Boehrer S, Bojunga J, Stieler M, Rummel MJ, Fauth F, Schneider B, Martin H, Hoelzer D, Weidmann E, Mitrou PS.

Leuk Lymphoma. 2002 Feb;43(2):377-84.

PMID:
11999573
50.

The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia.

Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L.

Leukemia. 2002 May;16(5):846-54.

Supplemental Content

Loading ...
Support Center